NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
Myeloma UK Publication, intended for UK Audience: Myeloma – An Introduction - Myeloma Essentials
NCCN GUIDELINES FOR PATIENTS: MULTIPLE MYELOMA 2023
What is Multiple Myeloma? www.uptodate.com
Explore MCT: Join us in creating the most comprehensive platform for Myeloma Clinical Trials
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj - Monoclonal Ab - Immunotherapy
Patient Education: Lenalidomide - Immunomodulatory Agents - IMIDS
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor
NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy
Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
Why is it important to become your own best advocate? HealthTree University Myeloma
What is a Myeloma Specialist Why do I Need one and How do I Find One? HealthTree University Myeloma
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
Patient Education: Dexamethasaone (Decadron) and other Steroids
HealthTree Myeloma Round Table in Buffalo on September 17, 2022 / 09:00AM - 03:00PM EDT
NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT